The pharmaceutical industry is experiencing a defining transformation as the first patient recently began treatment in the GENESIS-IPF-3 Phase III clinical trial. Academician Nanshan Zhong and President Chang Chen are among the elite medical professionals overseeing the multi-center clinical effort
While immunotherapy was previously confined to treating advanced stages of the disease, new evidence shows its efficacy in earlier, resectable settings. Gastric cancer has long remained a formidable opponent within the global oncology landscape, currently ranking as the fifth most common cancer
While medication abortion is FDA-approved for use up to eleven weeks of pregnancy, a new legal effort argues that state-level bans are being undermined by mail-order access. This challenge, currently centered in Louisiana, targets the regulatory framework that allows physicians to prescribe
The integration of proteomic aging clocks represents a fundamental shift in how the pharmaceutical industry approaches the treatment of chronic decay. For decades, the pursuit of longevity-enhancing therapies was throttled by the absence of a reliable, unified metric of biological age, forcing
The shift from digital molecular design to physical realization is becoming increasingly accessible as automated lab hardware follows the rapid growth of AI software. This convergence has allowed independent researchers to bypass the gatekeepers of traditional pharmaceutical institutions,
The rhythmic twitch of a scorpion’s tail has long signaled a lethal threat to the unwary, but today that same biological weaponry is being repurposed into a sophisticated pharmaceutical instrument for mending the human liver. While these arachnids have survived for hundreds of millions of years by
